The Good:
* pursuing Gyrase Gram Negative (assume they're targeting non dilutive BARDA funding) but how advanced are they?
* Cash conserving
The Bad:
* They can't find a partner for HRV
The Ugly:
* Another RSV candidate bites the dust (how advanced are these backups?).
* HRV uncertainty. Will they continue pursuing it?
The Good:* pursuing Gyrase Gram Negative (assume they're...
Add to My Watchlist
What is My Watchlist?